RANI
NASDAQRani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc. (RANI) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 4 wire items for RANI, including 2 SEC filings, 1 press release or news item and 1 earnings update. The most recent was published Nov 9, 2026.
Financial highlights
Full financials- Revenue, TTM
- $6.58M
- Revenue growth
- +448.7%
- Net income, TTM
- -$34.47M
- Net margin
- -523.5%
- Free cash flow, TTM
- -$23.22M
- Cash
- $3.62M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks42-25%
2026-05-172026-11-08
Mix1390d
- SEC Filings4(31%)
- Other4(31%)
- Insider2(15%)
- Offering1(8%)
- Analyst1(8%)
- Earnings1(8%)
Activity · 52 weeks6842 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 10-Q filed by Rani Therapeutics Holdings Inc.10-Q - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
- SECRani Therapeutics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
- PRRani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate Update~ Accepted into the U.S. FDA’s Emerging Technology Program (ETP), enabling early FDA engagement to support development of the RaniPill® platform technology ~ ~ Enrollment continues in RT-114 Phase 1a expansion cohort; data expected by end of 2026 ~ ~ Cash, cash equivalents and marketable securities of $45.3 million as of September 30, 2026; expect to fund operations at least through the end of 2027 ~ FREMONT, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update
- PRRani Therapeutics to Participate in the Chardan Healthcare ConferenceSAN JOSE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in a fireside chat at the upcoming Chardan Healthcare Conference. Details below: Chardan Healthcare Conference Date: Tuesday, October 20, 2026 at 1:00pm E.T.Location: New York, New YorkPresenter: Chief Executive Officer, Talat Imran, Chief Financial Officer, Nicholas Maestas, and Chief Business Officer, Kate McKinleyFormat: Fireside Chat and 1x1 Meetings Interested parties can access the live webcast for this conference from the Investor Relati
- PRRani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the RaniPill® Capsule™ platform technology has been accepted into the U.S. Food and Drug Administration (FDA) Emerging Technology Program (ETP). The FDA’s Emerging Technology Program, administered within the Agency’s Center for Drug Evaluation and Research (CDER), is designed to support the development and implementation of innovative approaches to pharmaceutical product design and manufacturing. Technologies accepted into the program must demonstrate the potential to improve pharmaceutical
- INSIDERChief Executive Officer Imran Talat covered exercise/tax liability with 7,928 shares, decreasing direct ownership by 2% to 461,808 units (SEC Form 4) to satisfy withholding obligation4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERChief Technical Officer Javadi Alireza covered exercise/tax liability with 309 shares, decreasing direct ownership by 3% to 9,071 units (SEC Form 4) (for tax liability)4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- PRRani Therapeutics to Participate in Upcoming September ConferencesSAN JOSE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in the upcoming September conferences. 10th Annual Best Ideas Growth (BIG10) Conference hosted by Lake Street Capital MarketsDate: Thursday, September 10, 2026 Format: 1x1 MeetingsLocation: New York, NY H.C. Wainwright 28th Annual Global Investment ConferenceFireside Chat: Monday, September 14, 2026 at 4:00pm E.T.Presenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Nicholas MaestasFormat: Fireside Chat and 1x1 Meetings
- ANALYSTChardan Capital Markets initiated coverage on Rani Therapeutics with a new price targetChardan Capital Markets initiated coverage of Rani Therapeutics with a rating of Buy and set a new price target of $6.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Rani Therapeutics Holdings Inc.SCHEDULE 13G/A - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)
- SECSEC Form 10-Q filed by Rani Therapeutics Holdings Inc.10-Q - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
- SECRani Therapeutics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
- PRRani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~ ~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~ ~ Completed a $20 million registered direct offering ~ ~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill® platform ~ ~ Appointed Nicholas Maestas as Chief Financial Officer and Michelle Gilson to Board of Directors ~ SAN JOSE, Calif., Aug. 1
- PRRani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth ConferenceSAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in the upcoming Canaccord Genuity 46th Annual Growth Conference. Details below: Canaccord Genuity 46th Annual Growth ConferenceDate: Wednesday, August 12, 2026 at 2:30pm E.T.Location: Boston, MAPresenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Nicholas MaestasFormat: Presentation and 1x1 Meetings Interested parties can access the live webcast for this conference from the Investor Relations section of the company's
- INSIDERSEC Form 4 filed by Director Gilson Michelle4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gilson Michelle3 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- SECSEC Form 8-K filed by Rani Therapeutics Holdings Inc.8-K - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
- PRRani Therapeutics Appoints Michelle Gilson to Board of DirectorsSAN JOSE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced the appointment of Michelle Gilson to its Board of Directors. Ms. Gilson will serve as Chair of the Audit Committee. "The combination of deep capital markets expertise and hands-on financial leadership at a high-growth biotechnology company makes Michelle an exceptional addition to our Board," said Talat Imran, Chief Executive Officer of Rani Therapeutics. "Her experience guiding Arcellx through its partnership and acquisition by Gilead gives her a firsthand understanding of how disciplined finan
- INSIDERDirector Imran Mir A bought $24,840 worth of shares (36,000 units at $0.69), increasing direct ownership by 2% to 2,119,334 units (SEC Form 4)4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERChief Technical Officer Javadi Alireza sold $301 worth of shares (386 units at $0.78) and covered exercise/tax liability with 309 shares, decreasing direct ownership by 7% to 9,380 units (SEC Form 4) (withholding obligation)4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERChief Executive Officer Imran Talat bought $25,193 worth of shares (35,000 units at $0.72), increasing direct ownership by 8% to 469,736 units (SEC Form 4)4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERChief Executive Officer Imran Talat sold $11,300 worth of shares (8,014 units at $1.41) and covered exercise/tax liability with 52,001 shares, decreasing direct ownership by 12% to 434,736 units (SEC Form 4) (withholding obligation)4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Maestas Nicholas4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- PRRani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics"; "Rani" or the "Company") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported that it granted an equity award in the form of a stock option to purchase 2,000,000 shares of Rani Class A common stock to Nicholas Maestas, Rani’s new Chief Financial Officer, as an inducement material to his acceptance of employment with Rani. The stock option was granted on July 17, 2026. The stock option has an exercise price of $0.6973 per share, which is equal to the closing price of Rani’s Class A common stock on the grant date, h
- SECSEC Form S-8 filed by Rani Therapeutics Holdings Inc.S-8 - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
RANI FAQ
11 questionsWhat does Rani Therapeutics Holdings Inc. do?
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a...What is the latest news on RANI?
In the last 30 days Quantisnow tracked 4 wire items for RANI: 2 SEC filings, 1 press release or news item and 1 earnings update. The most recent was published on November 9, 2026.What is RANI revenue?
Rani Therapeutics Holdings Inc. (RANI) reported $6.58M of revenue for the twelve months ended Sep 30, 2026. That is up 448.7% from the year before. Revenue for fiscal 2025 was $1.63M.Is RANI profitable?
No. Rani Therapeutics Holdings Inc. reported a net loss of $34.47M for the twelve months ended Sep 30, 2026.How much cash and debt does RANI have?
Rani Therapeutics Holdings Inc. reported $3.62M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does RANI stock trade?
Rani Therapeutics Holdings Inc. (RANI) is listed on NASDAQ.What sector and industry is RANI in?
Rani Therapeutics Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Rani Therapeutics Holdings Inc. go public?
Rani Therapeutics Holdings Inc. (RANI) completed its IPO in 2021.What are analysts saying about RANI?
Rani Therapeutics Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from Chardan Capital Markets: Buy with a $6.00 price target on 2026-08-18. Recent price targets range from $6.00 to $24.00.What companies are similar to RANI?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare RANI side-by-side with any of them on Quantisnow.How can I track RANI on Quantisnow?
Quantisnow aggregates Rani Therapeutics Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RANI to receive live email and push alerts on every new disclosure.